Immunotherapy Drugs Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Immunotherapy Drugs Market to 2027 - Global Analysis and Forecasts By Drug Type (Vaccines, Monoclonal Antibodies, Checkpoint Inhibitors, Interferons Alpha and Beta, Interleukins, Others); Therapeutic Area (Autoimmune and Inflammatory Diseases, Cancer, Infectious Diseases, Others); End User (Hospitals, Research Centers, Others)

Report Code: TIPRE00003416 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Immunotherapy or immunotherapy drug, is known as biologic therapy which is type of cancer treatment. The treatment enhances the body's natural defenses to fight cancer. It utilizes the biological substances to improve immune system function. It works by the stopping the growth of cancer cells and helping immune system to work better at destroying cancer cells. There are various types of immunotherapy which include oncolytic virus therapy, monoclonal antibodies, non-specific immunotherapies, T-cell therapy and cancer vaccines.

MARKET DYNAMICS
The immunotherapy drug market is anticipated to grow in the forecast period owing to driving factors such as rising prevalence of cancer worldwide, advancement in the development techniques and others. The biotechnological techniques are likely to create advanced techniques for the growth of the market during the forecast period.

MARKET SCOPE
The "Global Immunotherapy Drug Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of immunotherapy drug market with detailed market segmentation by drug type, therapeutic area, end user and geography. The global immunotherapy drug market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading immunotherapy drug market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global immunotherapy drug market is segmented on the basis of drug type, therapeutic area and end user. Based on drug type, the market is segmented as vaccines, monoclonal antibodies, checkpoint inhibitors, interferons alpha & beta, interleukins and others. On the basis of the therapeutic area the segment is classified as autoimmune and inflammatory diseases, cancer, infectious diseases and others. On the basis of the end user segment is divided into hospitals, research centers and others.


REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global immunotherapy drug market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The immunotherapy drug market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting immunotherapy drug market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the immunotherapy drug market in these regions.


MARKET PLAYERS

The reports cover key developments in the immunotherapy drug market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from immunotherapy drug market are anticipated to lucrative growth opportunities in the future with the rising demand for immunotherapy drug market in the global market. Below mentioned is the list of few companies engaged in the immunotherapy drug market.

The report also includes the profiles of key immunotherapy drug market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

• Eli Lilly and Company
• Astrazeneca
• Abbvie
• Amgen inc
• GlaxoSmithKline Plc
• Novartis International AG
• Merck and Co., Inc
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb
• UbiVac

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Immunotherapy Drugs Market - By Drug Type
1.3.2 Immunotherapy Drugs Market - By Therapeutic Area
1.3.3 Immunotherapy Drugs Market - By End User
1.3.4 Immunotherapy Drugs Market - By Region
1.3.4.1 By Country

2. KEY TAKEWAYS

3. RESEARCH METHODOLOGY

4. IMMUNOTHERAPY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.3.1 North America - Pest Analysis
4.3.2 Europe - Pest Analysis
4.3.3 Asia-Pacific - Pest Analysis
4.3.4 Middle East and Africa - Pest Analysis
4.3.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. IMMUNOTHERAPY DRUGS MARKET - KEY MARKET DYNAMICS

5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. IMMUNOTHERAPY DRUGS MARKET - GLOBAL MARKET ANALYSIS

6.1. IMMUNOTHERAPY DRUGS - GLOBAL MARKET OVERVIEW
6.2. IMMUNOTHERAPY DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. IMMUNOTHERAPY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG TYPE

7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. VACCINES
7.3.1. Overview
7.3.2. Vaccines Market Forecast and Analysis
7.4. MONOCLONAL ANTIBODIES
7.4.1. Overview
7.4.2. Monoclonal Antibodies Market Forecast and Analysis
7.5. CHECKPOINT INHIBITORS
7.5.1. Overview
7.5.2. Checkpoint Inhibitors Market Forecast and Analysis
7.6. INTERFERONS ALPHA AND BETA
7.6.1. Overview
7.6.2. Interferons Alpha and Beta Market Forecast and Analysis
7.7. INTERLEUKINS
7.7.1. Overview
7.7.2. Interleukins Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis

8. IMMUNOTHERAPY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC AREA

8.1. OVERVIEW
8.2. THERAPEUTIC AREA MARKET FORECASTS AND ANALYSIS
8.3. AUTOIMMUNE AND INFLAMMATORY DISEASES
8.3.1. Overview
8.3.2. Autoimmune and Inflammatory Diseases Market Forecast and Analysis
8.4. CANCER
8.4.1. Overview
8.4.2. Cancer Market Forecast and Analysis
8.5. INFECTIOUS DISEASES
8.5.1. Overview
8.5.2. Infectious Diseases Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis

9. IMMUNOTHERAPY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - END USER

9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. RESEARCH CENTERS
9.4.1. Overview
9.4.2. Research Centers Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis

10. IMMUNOTHERAPY DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS

10.1. NORTH AMERICA
10.1.1 North America Immunotherapy Drugs Market Overview
10.1.2 North America Immunotherapy Drugs Market Forecasts and Analysis
10.1.3 North America Market Forecasts and Analysis - By Drug Type
10.1.4 North America Market Forecasts and Analysis - By Therapeutic Area
10.1.5 North America Market Forecasts and Analysis - By End User
10.1.6 North America Market Forecasts and Analysis - By Countries
10.1.6.1 United States Market
10.1.6.1.1 United States Market by Drug Type
10.1.6.1.2 United States Market by Therapeutic Area
10.1.6.1.3 United States Market by End User
10.1.6.2 Canada Market
10.1.6.2.1 Canada Market by Drug Type
10.1.6.2.2 Canada Market by Therapeutic Area
10.1.6.2.3 Canada Market by End User
10.1.6.3 Mexico Market
10.1.6.3.1 Mexico Market by Drug Type
10.1.6.3.2 Mexico Market by Therapeutic Area
10.1.6.3.3 Mexico Market by End User
10.2. EUROPE
10.2.1 Europe Immunotherapy Drugs Market Overview
10.2.2 Europe Immunotherapy Drugs Market Forecasts and Analysis
10.2.3 Europe Market Forecasts and Analysis - By Drug Type
10.2.4 Europe Market Forecasts and Analysis - By Therapeutic Area
10.2.5 Europe Market Forecasts and Analysis - By End User
10.2.6 Europe Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Market
10.2.6.1.1 Germany Market by Drug Type
10.2.6.1.2 Germany Market by Therapeutic Area
10.2.6.1.3 Germany Market by End User
10.2.6.2 France Market
10.2.6.2.1 France Market by Drug Type
10.2.6.2.2 France Market by Therapeutic Area
10.2.6.2.3 France Market by End User
10.2.6.3 Italy Market
10.2.6.3.1 Italy Market by Drug Type
10.2.6.3.2 Italy Market by Therapeutic Area
10.2.6.3.3 Italy Market by End User
10.2.6.4 Spain Market
10.2.6.4.1 Spain Market by Drug Type
10.2.6.4.2 Spain Market by Therapeutic Area
10.2.6.4.3 Spain Market by End User
10.2.6.5 United Kingdom Market
10.2.6.5.1 United Kingdom Market by Drug Type
10.2.6.5.2 United Kingdom Market by Therapeutic Area
10.2.6.5.3 United Kingdom Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Immunotherapy Drugs Market Overview
10.3.2 Asia-Pacific Immunotherapy Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Market Forecasts and Analysis - By Drug Type
10.3.4 Asia-Pacific Market Forecasts and Analysis - By Therapeutic Area
10.3.5 Asia-Pacific Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Market
10.3.6.1.1 Australia Market by Drug Type
10.3.6.1.2 Australia Market by Therapeutic Area
10.3.6.1.3 Australia Market by End User
10.3.6.2 China Market
10.3.6.2.1 China Market by Drug Type
10.3.6.2.2 China Market by Therapeutic Area
10.3.6.2.3 China Market by End User
10.3.6.3 India Market
10.3.6.3.1 India Market by Drug Type
10.3.6.3.2 India Market by Therapeutic Area
10.3.6.3.3 India Market by End User
10.3.6.4 Japan Market
10.3.6.4.1 Japan Market by Drug Type
10.3.6.4.2 Japan Market by Therapeutic Area
10.3.6.4.3 Japan Market by End User
10.3.6.5 South Korea Market
10.3.6.5.1 South Korea Market by Drug Type
10.3.6.5.2 South Korea Market by Therapeutic Area
10.3.6.5.3 South Korea Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Immunotherapy Drugs Market Overview
10.4.2 Middle East and Africa Immunotherapy Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Market Forecasts and Analysis - By Drug Type
10.4.4 Middle East and Africa Market Forecasts and Analysis - By Therapeutic Area
10.4.5 Middle East and Africa Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Market
10.4.6.1.1 South Africa Market by Drug Type
10.4.6.1.2 South Africa Market by Therapeutic Area
10.4.6.1.3 South Africa Market by End User
10.4.6.2 Saudi Arabia Market
10.4.6.2.1 Saudi Arabia Market by Drug Type
10.4.6.2.2 Saudi Arabia Market by Therapeutic Area
10.4.6.2.3 Saudi Arabia Market by End User
10.4.6.3 U.A.E Market
10.4.6.3.1 U.A.E Market by Drug Type
10.4.6.3.2 U.A.E Market by Therapeutic Area
10.4.6.3.3 U.A.E Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Immunotherapy Drugs Market Overview
10.5.2 South and Central America Immunotherapy Drugs Market Forecasts and Analysis
10.5.3 South and Central America Market Forecasts and Analysis - By Drug Type
10.5.4 South and Central America Market Forecasts and Analysis - By Therapeutic Area
10.5.5 South and Central America Market Forecasts and Analysis - By End User
10.5.6 South and Central America Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Market
10.5.6.1.1 Brazil Market by Drug Type
10.5.6.1.2 Brazil Market by Therapeutic Area
10.5.6.1.3 Brazil Market by End User
10.5.6.2 Argentina Market
10.5.6.2.1 Argentina Market by Drug Type
10.5.6.2.2 Argentina Market by Therapeutic Area
10.5.6.2.3 Argentina Market by End User

11. INDUSTRY LANDSCAPE

11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. IMMUNOTHERAPY DRUGS MARKET, KEY COMPANY PROFILES

12.1. ELI LILLY AND COMPANY
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ASTRAZENECA
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ABBVIE
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. AMGEN INC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. NOVARTIS INTERNATIONAL AG
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. MERCK AND CO., INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. F. HOFFMANN-LA ROCHE AG
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. BRISTOL-MYERS SQUIBB
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10 UBIVAC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Eli Lilly and Company
2. Astrazeneca
3. Abbvie
4. Amgen inc
5. GlaxoSmithKline Plc
6. Novartis International AG
7. Merck and Co., Inc
8. F. Hoffmann-La Roche AG
9. Bristol-Myers Squibb
10. UbiVac